OA11150A - Polymorph of zopolrestat monohydrate - Google Patents

Polymorph of zopolrestat monohydrate Download PDF

Info

Publication number
OA11150A
OA11150A OA9900185A OA9900185A OA11150A OA 11150 A OA11150 A OA 11150A OA 9900185 A OA9900185 A OA 9900185A OA 9900185 A OA9900185 A OA 9900185A OA 11150 A OA11150 A OA 11150A
Authority
OA
OAPI
Prior art keywords
solution
dihydro
oxo
benzothiazolyl
methyl
Prior art date
Application number
OA9900185A
Other languages
English (en)
Inventor
John Francis Lambert
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11150A publication Critical patent/OA11150A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
OA9900185A 1998-08-21 1999-08-19 Polymorph of zopolrestat monohydrate OA11150A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
OA11150A true OA11150A (en) 2003-04-16

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900185A OA11150A (en) 1998-08-21 1999-08-19 Polymorph of zopolrestat monohydrate

Country Status (31)

Country Link
US (1) US6159976A (zh)
EP (1) EP0982306A3 (zh)
JP (1) JP2000072769A (zh)
KR (1) KR20000017411A (zh)
CN (1) CN1245804A (zh)
AP (1) AP9901662A0 (zh)
AU (1) AU4453299A (zh)
BG (1) BG103674A (zh)
BR (1) BR9903873A (zh)
CA (1) CA2280590A1 (zh)
EA (1) EA199900675A3 (zh)
EE (1) EE9900385A (zh)
GT (1) GT199900137A (zh)
HR (1) HRP990259A2 (zh)
HU (1) HUP9902783A3 (zh)
ID (1) ID23307A (zh)
IL (1) IL131419A0 (zh)
IS (1) IS5155A (zh)
MA (1) MA26678A1 (zh)
NO (1) NO994027L (zh)
NZ (1) NZ337363A (zh)
OA (1) OA11150A (zh)
PA (1) PA8480601A1 (zh)
PE (1) PE20000993A1 (zh)
PL (1) PL335016A1 (zh)
SG (1) SG83147A1 (zh)
TN (1) TNSN99159A1 (zh)
TR (1) TR199901996A2 (zh)
UY (1) UY25668A1 (zh)
YU (1) YU39899A (zh)
ZA (1) ZA995297B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5934206B2 (ja) 2010-07-16 2016-06-15 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク アルドース還元酵素阻害剤および同使用方法
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US20140228319A1 (en) * 2013-02-13 2014-08-14 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
IL304979A (en) 2016-06-21 2023-10-01 Univ Columbia Aldose reductase inhibitors and methods of using them
PT3658142T (pt) 2017-07-28 2024-06-27 Applied Therapeutics Inc Composições e métodos para tratar galactosemia
AU2020254610A1 (en) 2019-04-01 2021-11-18 Applied Therapeutics Inc. Inhibitors of aldose reductase
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
AU2021264454A1 (en) 2020-05-01 2022-12-08 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
SG83147A1 (en) 2001-09-18
TNSN99159A1 (fr) 2005-11-10
HUP9902783A2 (hu) 2000-12-28
MA26678A1 (fr) 2004-12-20
NO994027D0 (no) 1999-08-20
PE20000993A1 (es) 2000-10-04
PL335016A1 (en) 2000-02-28
ZA995297B (en) 2001-02-19
EE9900385A (et) 2000-04-17
HUP9902783A3 (en) 2001-01-29
IL131419A0 (en) 2001-01-28
AU4453299A (en) 2000-03-09
KR20000017411A (ko) 2000-03-25
NO994027L (no) 2000-02-22
BG103674A (en) 2000-03-31
BR9903873A (pt) 2000-09-19
CA2280590A1 (en) 2000-02-21
HRP990259A2 (en) 2000-06-30
JP2000072769A (ja) 2000-03-07
AP9901662A0 (en) 1999-09-30
HU9902783D0 (en) 1999-10-28
TR199901996A2 (xx) 2000-03-21
EP0982306A2 (en) 2000-03-01
EA199900675A3 (ru) 2000-06-26
EP0982306A3 (en) 2000-07-05
CN1245804A (zh) 2000-03-01
IS5155A (is) 2000-02-22
UY25668A1 (es) 2001-08-27
YU39899A (sh) 2002-12-10
US6159976A (en) 2000-12-12
GT199900137A (es) 2001-02-09
PA8480601A1 (es) 2000-09-29
EA199900675A2 (ru) 2000-02-28
ID23307A (id) 2000-04-05
NZ337363A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
US10639306B2 (en) Aldose reductase inhibitors and uses thereof
US11498925B2 (en) Aldose reductase inhibitors and methods of use thereof
EP2593456B1 (en) Aldose reductase inhibitors and uses thereof
US20020111373A1 (en) Hydrochloride salt of a fused heterocyclic compound
JPH0141629B2 (zh)
OA11150A (en) Polymorph of zopolrestat monohydrate
JP2001514632A (ja) 新規ヘテロサイクリック化合物
US6753334B2 (en) Preparation of sodium-hydrogen exchanger type-1 inhibitors
EP2594570B1 (en) Crystal of thienopyrimidine derivative
US5217982A (en) Compounds having antihypertensive properties
JP3195455B2 (ja) キノリン−3−酢酸誘導体、その製造法と用途
MXPA99007842A (en) Polymopher of monopidrate of zopolres
ZA200402621B (en) Intermediates for preparing glycogen phosphorylase inhibitors.
CZ9902918A3 (cs) Polymorfy monohydrátu zopolrestatu, farmaceutické kompozice na jejich bázi a způsob jejich výroby
JPH0451527B2 (zh)
JPH03148262A (ja) イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
JP2001089372A (ja) 癌の予防剤及び治療剤